GlobeNewsWire
20 Oct 2026, 19:45 UTC · 1h ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines – HIMS
Impact · against what's priced in
The filing of a new class action lawsuit by Pomerantz LLP is not a catalyst for HIMS, as the market has already priced in significant legal and regulatory friction. The current valuation explicitly accounts for ongoing litigation drag and avoids assuming a clean resolution to such disputes.
- HIMS−0.05
Already priced in
- The price assumes
Significant legal and regulatory friction, including FTC lawsuits over data privacy and billing practices.





